Translational Medical Research Commons^™

Nccn Intermediate Risk Prostate Cancer- Long-Term Outcomes Of Active Surveillance Compared To Active Treatment, A Population-Based Analysis, Adam Schneider, Thenappan Chandrasekar, Nicholas Bowler, Hanan Goldberg, James R. Mark, Edouard J. Trabulsi, Costas D. Lallas, Leonard G. Gomella

Phase 1

Background: While active surveillance (AS) is an established standard of care for low-risk (LR) prostate cancer (PCa), its utility for intermediate risk (IR) PCa is less evident. Prior studies were limited by the inability to differentiate between AS and watchful waiting (WW). Using a recent update in the Surveillance, Epidemiology and End Results (SEER) Database that allows for enhanced distinction between AS and WW, we aimed to compare survival outcomes of men with LR and IR PCa treated with either AS, WW or active treatment (AT).

Methods: 166,244 men were initially identified by biopsy Gleason Grade Group (GG) alone – …